Alnylam Pharmaceuticals (NASDAQ:ALNY) Raised to Overweight at JPMorgan Chase & Co.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, MarketBeat reports. The firm currently has a $328.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $280.00. JPMorgan Chase […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, MarketBeat reports. The firm currently has a $328.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $280.00. JPMorgan Chase […]
